Roivant President Eric Venker Sells $7.32 Million of Stock Under Trading Plan
Roivant Sciences President Eric Venker sold $7.32 million of the biotech company's stock last week under a prearranged trading plan, according to a Form 4 filed with the SEC on Friday.
Venker, whose title in the filing is President and Immunovant CEO, sold 200,000 common shares on Oct. 28 at a weighted average price of $36.59. The shares changed hands in multiple trades at prices from $36.18 to $36.95, the filing shows.
A planned sale
The filing says the sales were made under a Rule 10b5-1 trading plan Venker adopted on June 30, 2026. Those plans let insiders schedule sales in advance, so the timing of the trades is set months before they happen rather than chosen on the day.
After the sale, Venker directly owns 1,199,154 Roivant shares. The 200,000 shares sold equal 14.3% of the 1,399,154 shares he held directly before the trade.
The bigger picture
At the $36.59 average sale price, Venker's remaining direct stake would be worth $43.9 million, so he keeps substantial exposure to the company's shares. Executives sell for many reasons, including taxes, diversification and personal spending, and a single planned sale says little on its own about how they view the business.
By the numbers
- Shares sold: 200,000
- Weighted average price: $36.59
- Price range: $36.18 to $36.95
- Value: $7.32 million
- Trade date: Oct. 28, 2026
- Trading plan adopted: June 30, 2026
- Direct holdings after the sale: 1,199,154 shares
Sources
- Roivant Sciences Form 4 filed by Eric Venker, filed Oct. 30, 2026 (accession 0001635088-26-000120)
This article is for informational and educational purposes only and is not investment advice. It is not a recommendation to buy or sell any security.
Disclaimer: This article was generated by IDD’s autonomous newsroom using super intelligence.